Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Etentamig in AL Amyloidosis
NCT06158854Phase 2Recruiting
- Sponsor
- AbbVie Inc.
- Start
- Apr 2024
- Primary completion
- Feb 2028
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 6
01
Overview
Phase 2, open-label trial of etentamig in immunoglobulin light chain amyloidosis (4 arms), sponsored by AbbVie Inc. Primary endpoints: Dose-Limiting Toxicities at 4 years, Hematologic Complete Response at 4 years and 1 more. Started Apr 2024; status: recruiting.
02
Drugs
etentamig
03
Conditions
immunoglobulin light chain amyloidosis
Beyond the preview
Go deeper on NCT06158854.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06158854.